Navigation Links
ChanTest to Highlight Most-Comprehensive Range of Ion Channel Profiling Screens and Consultation Services at 14th Annual SBS Conference, Booth 1104

CLEVELAND, March 25 /PRNewswire/ -- ChanTest, the leading provider of ion channel testing services for drug-discovery and development applications, will feature at the SBS conference the company's expanding line of ion channel services designed to give drug-discovery researchers the early information they need to identify the most promising compounds, and eliminate those that could be harmful -- before they invest millions in the drug-development process. The 14th Annual Society for Biomolecular Sciences (SBS) Conference takes place April 6-10, 2008, at the America's Center Convention Complex in St. Louis, Missouri. ChanTest is exhibiting in booth 1104.

"When completed early in the drug-discovery process, ChanTest's functional ion channel screens can save considerable time, money, and other resources," said Dr. Arthur (Buzz) Brown, founder and CEO of ChanTest. "Our automated and manual patch clamp profiling screens provide more-accurate results than binding screens since results are generated by measuring the functional effects of drugs directly on ion channel currents. For higher-throughput screening, we use FLIPRTetra(R) to measure membrane potential and potassium flux for voltage-gated and calcium-activated potassium channels. Too often, researchers identify unacceptable safety risks late in the drug-development process -- during the GLP (Good Laboratory Practices) patch-clamp studies that are required by the FDA for an IND (Investigational New Drug) submission. Using our functional screens during the discovery profiling process helps avoid this situation."

Dr. Brown continued, "Unlike most service organizations, ChanTest has validated its cell lines for testing at each phase of the drug-discovery process. Whether customers need initial high-throughput screening of hits, high-sensitivity screens for lead identification and lead optimization, or safety testing in preparation for an IND submission -- our results will correlate. We tailor each customer's service program to meet their discovery and budgetary goals. We're proud of the reputation we've built over the past 10 years -- delivering fast, accurate, and reliable results on thousands of compounds to pharmaceutical and biotechnology customers worldwide. We don't just deliver raw data -- our ion channel experts tell customers what the results mean."

ChanTest scientists were the first to prove hERG as the target for adverse cardiac events linked to non-cardiac drugs: Seldane (terfenadine), Propulsid (cisapride), and Nizoral (ketoconazole), and ChanTest pioneered the development of functional, cell-based ion channel testing as a means to predict cardiac side effects produced by non-cardiac drugs. Such testing is now a standard component of regulatory submissions prior to the approval of drugs for use in humans. ChanTest is committed to innovation, and is leading the next major advance in ion channel research and services with a $10 million program to develop the world's most extensive library or catalog of ion channels. ChanTest's expert electrophysiologists fully validate the ion channels for interrogation with functional, pharmacological, and biochemical assays.

About ChanTest

The preeminent ion channel services company, ChanTest serves its drug discovery and development customers with GLP safety and automated screening assays using its library of ion channel-expressing cell lines -- the most comprehensive in the world. Since its inception in 1998, ChanTest has tested more than 12,000 compounds for more than 250 global pharmaceutical and biotech companies -- helping them to achieve their drug safety and discovery goals. ChanTest works in partnership with customers to speed the drug-development process, save time and money, and ultimately -- to help make better, safer drugs. Because of ChanTest's seminal role in this field, along with the company's uncompromising commitment to quality, ChanTest was named "most trusted fee-for-service provider" for ion channel screening in the HTStec Ion Channel Trends Survey for two years in a row. ChanTest is based in Cleveland, Ohio. For more information, please visit

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ChanTest to Highlight Expanded Ion Channel Testing Services for Preclinical Safety at ToxExpo, Including the Worlds Largest Catalog of Validated Ion Channels, Booth 2504
2. Helix BioPharma reports Q2 2008 highlights, financial results
3. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
4. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
5. MEDEA+ Noblanc award highlights improvements in microelectronics
6. National Nanotechnology Initiative releases its fiscal year 2009 budget and highlights
7. Coalition for a Competitive Pharmaceutical Market Launches New Print Ad Campaign Highlighting Need for Meaningful Biogenerics Legislation
8. CyberKnife Users Meeting Highlights Major Clinical Data Milestones and Emerging Trends
9. BioTrends Releases Fourth Annual Nephrology TreatmentTrends Publication Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
10. Oncothyreon highlights corporate and clinical objectives for 2008
11. CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium
Post Your Comments:
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
(Date:11/24/2015)... Florida (PRWEB) , ... November 24, 2015 , ... ... biggest event of the year and one of the premier annual events for ... and ran from 8–11 November 2015, where ISPE hosted the largest number of ...
(Date:11/24/2015)... , Nov. 24, 2015  Clintrax Global, Inc., a worldwide provider ... , today announced that the company has set a new ... 391% quarter on quarter growth posted for Q3 of 2014 to ... and Mexico , with the establishment of an ... 2015. --> United Kingdom and ...
(Date:11/24/2015)... ... November 24, 2015 , ... This fall, global software solutions ... in five states to develop and pitch their BIG ideas to improve health and ... are competing for votes to win the title of SAP's Teen Innovator, an all-expenses ...
Breaking Biology Technology:
(Date:11/17/2015)... , Nov. 17, 2015 Pressure BioSciences, Inc. ... the development and sale of broadly enabling, pressure cycling ... sciences industry, today announced it has received gross proceeds ... million Private Placement (the "Offering"), increasing the total amount ... or more additional closings are expected in the near ...
(Date:11/12/2015)...   Growing need for low-cost, easy to ... paving the way for use of biochemical sensors ... in clinical, agricultural, environmental, food and defense applications. ... medical applications, however, their adoption is increasing in ... emphasis on improving product quality and growing need ...
(Date:11/9/2015)... ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
Breaking Biology News(10 mins):